Received: 28 November 2019
Accepted: 3 August 2020
First Online: 20 August 2020
: The study is approved at the Hospital das Clínicas, University of São Paulo, School of Medicine. The number of study approval is CAAE 74305817.0.0000.0068.
: Written informed consent for publication was obtained from all included in the study.
: LOM receives fees from Novartis Brazil as speaker and received an award from the European Society for Primary Immunodeficiencies; MG receives fees as speaker and consultancies from Novartis and Sobi